-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

241 Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus AzacitidineClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome
Hematology Disease Topics & Pathways:
Clinical Trials, Clinical Research, Clinically Relevant
Saturday, December 11, 2021: 2:00 PM

Jacqueline S. Garcia, MD1, Andrew H. Wei, MBBS, PhD2, Meagan A. Jacoby3, Chun Yew Fong, MBBS BMedSci FRACP FRCPA PhD4, Uma Borate, MD5, Maria R. Baer, MD6, Ilona Cunningham7*, Olatoyosi Odenike, MD8, Joseph G. Jurcic, MD9, Daniel Nowak, MD10*, Pierre Peterlin11*, Uwe Platzbecker, MD12, Diana Dunshee, PhD13*, Ying Zhou, PhD14*, David Hoffman14*, Yan Sun, PhD14*, Relja Popovic14, Barrett Ainsworth14*, Kiran Naqvi, MD13*, Steve Kye14, Leah Hogdal, PhD14* and Guillermo Garcia-Manero, MD15

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2The Alfred Hospital and Monash University, Melbourne, Australia
3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA, St. Louis, MO
4Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia
5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
6Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
7Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
8University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL
9Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY
10Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany
11Nantes University Hospital, Nantes, France
12Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
13Genentech Inc., South San Francisco, CA
14AbbVie Inc., North Chicago, IL
15The University of Texas MD Anderson Cancer Center, Houston, TX

Introduction: Patients (pts) with higher-risk myelodysplastic syndromes (MDS) are typically treated with azacitidine (Aza). Venetoclax (Ven) is a selective, potent, oral BCL-2 inhibitor that has demonstrated synergy with Aza in preclinical studies of myeloid malignancies. Higher-risk MDS is associated with mutations in genes involved in RNA splicing, epigenetic regulation, transcription, and cellular signaling. Assessing the dynamics of genetic variants during treatment of higher-risk MDS enables understanding of the molecular determinants of response. This phase 1b study (NCT02942290) evaluates Ven + Aza for treatment-naïve higher-risk MDS, and we report efficacy among mutationally defined subgroups as well as the depth of molecular response.

Methods: Pts (≥18 years) with higher-risk MDS enrolled in the study had International Prognostic Scoring System intermediate-2 or high-risk MDS, bone marrow (BM) blasts <20% at baseline, and ECOG ≤2 performance status. Aza 75 mg/m2 was administered on Days (d) 1–7 of each 28-d cycle. The Ven RP2D was 400 mg x 14 d of each 28-d cycle. Primary objectives were to assess the Ven+Aza safety profile and to establish the RP2D. Key secondary objectives were to assess the overall response rate (ORR), defined as complete remission (CR), marrow CR and partial remission (PR), and overall survival. Analyses were carried out on all pts who received ≥1 dose of study drug and efficacy was evaluated per IWG 2006 response criteria.

Molecular responses were quantified by mutation analysis of baseline and serial BM aspirate (BMA) or peripheral blood (PB) samples collected at protocol-specified time points. Mutations were identified in BMA using Archer VariantPlex Myeloid 75-gene panel [limit of detection (LOD) 5%; time points: pre-treatment (n=43), on-treatment (n=32), and treatment completion visit (TCV) (n=25)] or TruSight Myeloid 54-gene Sequencing Panel in PB [LOD 2%; time points: pre-treatment (n=21), on-treatment (n=19), and TCV (n=8)] to assess molecular dynamics during Ven + Aza treatment. Molecular responses were only compared within the same tissue type.

Results: At the Dec 15, 2020 cutoff, 78 pts had received Ven+Aza, including 51 who received Ven at the RP2D of 400 mg x 14 d, with median follow up time of 23 mos (range 0.1–44.2). Median age was 70 years (range 26–87); 72% male; and 91% had excess BM blasts (>5 to ≤10%, n=21; >10 to ≤20%, n=49; >20%, n=1). For the entire population, mORR was 80% (CR 40% and mCR 40%; no PR). 42% with mCR also had hematologic improvement [HI].

Screening mutational profiling was performed on 46/51 pts who received the RP2D of Ven + Aza. The most common mutations were TP53 (26%), ASXL1 (24%), U2AF1 (17%), and RUNX1 (15%), consistent with a higher-risk MDS population. Clinical responses (CR + mCR) were observed across the mutational spectrum, including in pts with poor prognostic mutations in TP53 (83%), ASXL1 (82%), and RUNX1 (71%).

Sixty-four pts treated with Ven + Aza (all Ven dosing cohorts) had paired BMA or PB pre-treatment and on-treatment and/or end of study samples available for serial analysis at the Dec 15, 2020 data cutoff. Ven + Aza resulted in robust and rapid molecular responses across the mutational spectrum. Pts who achieved CR at the time of serial sample acquisition had more significant reduction of variant allele frequencies (VAFs) (n=18 pts, mean VAF pre-treatment = 38.3; mean VAF at CR = 11.8) compared to pts who achieved stable disease or HI (n=11 pts, mean VAF pre-treatment = 29.8; mean VAF at SD or HI = 24.0) or progressive disease (n=10 pts, mean VAF pre-treatment = 27.4; mean VAF at PD = 26.9).

Reductions of VAFs below the LOD were observed across the mutational spectrum, including in genes that are considered poor prognostic in higher-risk MDS (e.g., TP53, ASXL1 and RUNX1), demonstrating the broad molecular activity of Ven + Aza (Figure). Finally, molecular responses were observed quickly, with VAF reductions below the LOD observed as early as end of Cycle 1, consistent with the mechanism of action of Ven directly activating the mitochondrial apoptotic pathway in cells.

Conclusions: Pts with higher-risk MDS treated with Ven + Aza had rapid, durable responses and high remission rates. Pts across key mutational profiles achieved meaningful clinical and molecular responses, supporting an all-comers approach. Updated data will be presented, which will provide more follow up time and durability of responses among mutational subsets.

Disclosures: Garcia: Genentech: Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Research Funding; Prelude: Research Funding; Pfizer: Research Funding. Wei: Novartis, Celgene, AbbVie, Servier, AstraZeneca, and Amgen: Research Funding; Novartis, Janssen, Amgen, Roche, Pfizer, Abbvie, Servier, BMS, Macrogenics, Agios, Gilead: Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria. Jacoby: Abbvie: Research Funding; Jazz: Research Funding. Fong: Amgen, BMS: Speakers Bureau; AbbVie, Amgen, Novartis, Pfizer, Astellas: Honoraria; Amgen: Research Funding. Borate: Genentech: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz Pharma: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Blueprint Medicine: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding. Cunningham: AbbVie, Amgen, Astex, Celgene, Janssen, Novartis, Principia Biopharma, Rigel: Research Funding. Odenike: Celgene, Incyte, AstraZeneca, Astex, NS Pharma, AbbVie, Gilead, Janssen, Oncotherapy, Agios, CTI/Baxalta, Aprea: Research Funding; AbbVie, Celgene, Impact Biomedicines, Novartis, Taiho Oncology, Takeda: Consultancy. Jurcic: AbbVie, BMS/Celgene, Novartis: Consultancy; AbbVie, Arog Pharmaceuticals, Astellas, BMS/Celgene, Forma Therapeutics, Genentech, Gilead Sciences, PTC Therapeutics, Syros Pharmaceuticals: Research Funding. Nowak: Pharmaxis: Current holder of individual stocks in a privately-held company, Research Funding; AbbVie: Other: Investigator on funded clinical trial; Affimed: Research Funding; Tolero Pharma, Pharmaxis, Apogenix: Research Funding; Celgene: Honoraria; Takeda: Honoraria. Platzbecker: Janssen: Honoraria; Celgene/BMS: Honoraria; Geron: Honoraria; AbbVie: Honoraria; Novartis: Honoraria; Takeda: Honoraria. Dunshee: Genentech/Roche: Current Employment, Current equity holder in publicly-traded company. Zhou: AbbVie: Current Employment, Current holder of stock options in a privately-held company. Hoffman: AbbVie: Current Employment, Current holder of stock options in a privately-held company. Sun: AbbVie: Current Employment. Popovic: AbbVie: Current Employment, Current equity holder in publicly-traded company. Ainsworth: AbbVie: Current Employment, Current holder of stock options in a privately-held company. Naqvi: Genentech/Roche: Current Employment, Current holder of stock options in a privately-held company. Kye: AbbVie: Current Employment, Other: May hold equity. Hogdal: AbbVie: Current Employment, Current holder of stock options in a privately-held company.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH